H. pylori Treatment Recommendation
For treatment-naive adults with H. pylori infection, bismuth quadruple therapy (BQT) for 14 days is the preferred first-line regimen when antibiotic susceptibility is unknown. 1
First-Line Treatment Options
The 2024 ACG guideline establishes BQT as the gold standard because it:
- Maintains efficacy even in areas with high dual resistance to clarithromycin and metronidazole 2
- Remains effective despite in vitro metronidazole resistance 2
- Is the most cost-effective option from a healthcare payer perspective 3
Bismuth Quadruple Therapy (BQT) - Preferred
- Regimen: PPI (standard dose) twice daily + bismuth subsalicylate 300mg four times daily + metronidazole 500mg three-four times daily + tetracycline 500mg four times daily
- Duration: 14 days 2, 1
- Key advantage: Avoids antibiotic overuse concerns and works despite common resistance patterns
Alternative First-Line Options (When BQT Not Suitable)
Rifabutin triple therapy (14 days) is the preferred alternative for patients without penicillin allergy:
- Rifabutin 150mg twice daily + amoxicillin 1000mg twice daily + PPI twice daily
- Cost-effective alternative with high net monetary benefit 3
- Rifabutin and amoxicillin resistance remain rare 4
Potassium-competitive acid blocker (vonoprazan) dual therapy (14 days) is another suitable empiric alternative 1
Concomitant non-bismuth quadruple therapy (14 days) is appropriate in areas of high clarithromycin resistance where bismuth is unavailable:
- PPI twice daily + amoxicillin 1000mg twice daily + metronidazole 500mg twice daily + clarithromycin 500mg twice daily 2
Critical Pitfalls to Avoid
Do NOT use clarithromycin triple therapy unless:
- Patient has no previous macrolide exposure AND
- Local clarithromycin resistance is documented to be <15% 2, 5
- Clarithromycin resistance now exceeds 30% in the United States 6
Levofloxacin-based regimens are NOT first-line for most patients due to resistance rates exceeding 30% 6. All three major consensus groups (ACG, Toronto, Maastricht) agree levofloxacin should be reserved for salvage therapy 2
Treatment Duration
Always prescribe 14 days for first-line therapy 2, 1. The Toronto Consensus found sufficient evidence that 14 days achieves higher success than shorter durations, and the principle is to succeed on the first attempt to avoid retreatment, retesting, cost, and microbiome disruption 2.
PPI Dosing Considerations
Use standard-dose PPI twice daily, taken 30 minutes before eating on an empty stomach:
- Pantoprazole 40mg, lansoprazole 30mg, omeprazole 20mg, esomeprazole 20mg, dexlansoprazole 30mg, or rabeprazole 20mg 4
- Avoid concomitant use of H2-receptor antagonists 4
After First-Line Failure
If BQT fails, use levofloxacin triple therapy or rifabutin triple therapy for 14 days (if antibiotic susceptibility unknown) 1
If clarithromycin-containing regimen fails, use BQT or levofloxacin-based salvage regimen 4, 5
After two failed therapies with confirmed adherence, obtain H. pylori susceptibility testing to guide subsequent regimens 4. Salvage regimens containing clarithromycin or levofloxacin should only be used if antibiotic susceptibility is confirmed 1.
Evidence Quality Note
The 2024 ACG guideline 1 supersedes the 2017 version 5 and reflects current antimicrobial resistance patterns. Three new first-line options have been approved since 2017, and resistance to clarithromycin, levofloxacin, and metronidazole now exceeds 30% 6. Recent meta-analysis shows susceptibility-guided therapy achieves superior eradication versus empirical regimens, though the benefit is attenuated when BQT is the comparator 7.
Probiotics remain unproven for refractory H. pylori and should be considered experimental 4.